301 results
Page 6 of 16
8-K
EX-99.1
7kfd6c29xdw3fi
5 Feb 20
Trovagene to Present New Clinical Data for Onvansertib in Metastatic Castration-Resistant Prostate Cancer at ASCO Genitourinary Cancers Symposium
10:24am
8-K
EX-99.1
1uanku 85
29 Jan 20
Trovagene Receives Approximately $1.45 Million From Exercise of Warrants
10:51am
8-K
EX-99.1
0y88hu i6m
27 Jan 20
Other Events
10:59am
8-K
EX-99.1
tciglzclwy4cf9
21 Jan 20
Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposium
10:09am
8-K
EX-99.1
5hhilgx
13 Jan 20
Trovagene Oncology Investor Presentation January 2020
10:22am
8-K
EX-99.1
uxpk esrd
9 Dec 19
Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASH
2:49pm
8-K
EX-99.1
8is1vge5rz
4 Dec 19
Other Events
12:15pm
8-K
EX-99.1
dn7xah1
14 Nov 19
Other Events
9:07am
8-K
EX-99.1
58wqv7dt
7 Nov 19
Trovagene Announces Third Quarter 2019 Results and Highlights
4:21pm
8-K
EX-99.1
sfe f80cejntg
6 Nov 19
Trovagene Announces Data from Acute Myeloid Leukemia (AML) Phase 1b/2 Trial of Onvansertib Chosen for Oral Presentation at ASH 2019 Annual Meeting
12:41pm
8-K
EX-99.1
baroaged
28 Oct 19
Trovagene Announces $5.0 Million Private Placement PricedAt-the-Market
4:52pm
8-K
EX-10.1
0m8n6g0k
28 Oct 19
Trovagene Announces $5.0 Million Private Placement PricedAt-the-Market
4:52pm
8-K
EX-99.1
9403a
22 Oct 19
Trovagene Announces Positive Response to Treatment in Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer
10:30am
8-K
EX-9.01
7vpe4 bl2b
2 Oct 19
Other Events
10:33am
8-K
EX-9.01
6r2l g6viyutud
1 Oct 19
Other Events
10:50am
8-K
EX-9.01
b1kmtjg
30 Sep 19
Other Events
12:46pm
8-K
EX-99.1
p56 ohzv2
19 Sep 19
Other Events
10:06am
8-K
EX-99.1
n1h2klqzatdbvt5gss5
26 Aug 19
Other Events
1:50pm
8-K
EX-10.1
67n5indpf3116w33zp
21 Aug 19
Entry into a Material Definitive Agreement
8:25am